Fubotv earnings beat by $0.10, revenue topped estimates
Randall Moreadith, Chief Scientific Officer of Serina Therapeutics, Inc. (NASDAQ:SER), sold 5,500 shares of common stock on August 4, 2025, for a total of $28,435. The shares were sold at prices ranging from $5.13 to $5.35, with the current stock price at $5.26. The micro-cap company, valued at $53.33 million, currently shows weak financial health according to InvestingPro metrics, though analysts maintain price targets between $11-$15.
On the same day, Moreadith exercised options to acquire 5,500 shares of Serina Therapeutics common stock at a price of $0.06 per share, for a total of $330. Following these transactions, Moreadith directly holds 478,990 stock options. With earnings scheduled for August 7, InvestingPro subscribers can access comprehensive insider trading analysis and 11 additional key insights about SER’s financial outlook.
In other recent news, Serina Therapeutics, Inc. announced the advancement of its once-weekly injectable treatment, SER-270, for tardive dyskinesia. This product, also known as POZ-VMAT2i, utilizes Serina’s proprietary POZ polymer technology. The technology allows for weekly subcutaneous administration, which could serve as an alternative to daily oral medications, potentially benefiting patients who have difficulties adhering to their medication regimen. This development marks a significant step for the company in addressing the needs of patients with tardive dyskinesia.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.